| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Plasmodium Malaria TLRs SARS-COV-2 HIV-1
The primary targets of chloroquine-d5 are identical to those of chloroquine, as the deuterated form has the same mechanism of action. Chloroquine is an autophagy inhibitor and a toll-like receptor (TLR) inhibitor. It inhibits endosomal fusion and viral entry. Chloroquine-d5 is used in research applications rather than as a therapeutic agent. |
|---|---|
| ln Vitro |
In vitro activity of chloroquine-d5 is not studied as a primary endpoint; the deuterated compound is used as an internal standard in analytical methods. Chloroquine, the parent compound, has well-characterized in vitro activity against malaria parasites and other pathogens. Chloroquine-d5 serves as a reference standard for quantifying chloroquine in biological samples.
|
| ln Vivo |
In vivo activity of chloroquine-d5 is not studied as a therapeutic agent. The parent compound chloroquine has been extensively studied in vivo for its antimalarial and anti-inflammatory effects. Chloroquine-d5 is used in pharmacokinetic studies as an internal standard for the quantification of chloroquine in biological samples.
|
| Enzyme Assay |
For analytical method development, chloroquine-d5 is used as an internal standard for LC-MS/MS quantification of chloroquine in plasma, serum, or other biological matrices. The deuterated compound has identical chromatographic and mass spectrometric properties to the parent compound but can be distinguished by its mass shift. Standard protocols for bioanalytical method validation are followed.
|
| Cell Assay |
Chloroquine-d5 is used in bioanalytical laboratories rather than in cell-based studies. For cell-based studies of chloroquine activity, the parent compound is used. Standard protocols for antimalarial activity screening involve culturing Plasmodium falciparum and treating with chloroquine. EC₅₀ values are calculated from dose-response curves.
|
| Animal Protocol |
Chloroquine-d5 is not used in in vivo animal studies as a therapeutic agent. The parent compound chloroquine has been studied in animal models of malaria and autoimmune diseases. The deuterated form is used in pharmacokinetic studies as an internal standard for the quantification of chloroquine and its metabolites in animal samples.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of chloroquine-d5 are identical to those of chloroquine. Chloroquine is well absorbed after oral administration and has a long half-life. It is extensively distributed in tissues and eliminated primarily by renal excretion. Specific PK parameters have been extensively characterized.
|
| Toxicity/Toxicokinetics |
The toxicological profile of chloroquine-d5 is identical to that of chloroquine. Chloroquine has a well-characterized safety profile with known adverse effects including gastrointestinal disturbances, retinopathy, and cardiotoxicity. Comprehensive toxicological data are available from clinical use.
|
| References | |
| Additional Infomation |
Chloroquine-d5 is a stable isotope-labeled internal standard used in analytical chemistry for the quantification of chloroquine in biological samples. The deuterated compound is used in bioanalytical method development and validation, pharmacokinetic studies, and therapeutic drug monitoring. Chloroquine is an FDA-approved drug for the treatment of malaria and rheumatoid arthritis. Chloroquine-d5 is not a therapeutic agent and is not approved for clinical use.
|
| Molecular Formula |
C18H21D5CLN3
|
|---|---|
| Exact Mass |
324.212
|
| CAS # |
1854126-41-2
|
| Related CAS # |
Chloroquine phosphate;50-63-5;Chloroquine;54-05-7;Chloroquine dihydrochloride;3545-67-3;Chloroquine-d5 diphosphate;1854126-42-3
|
| PubChem CID |
76974641
|
| Appearance |
Colorless to light yellow liquid
|
| LogP |
4.6
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
22
|
| Complexity |
309
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])([2H])C([2H])([2H])N(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl
|
| InChi Key |
WHTVZRBIWZFKQO-SGEUAGPISA-N
|
| InChi Code |
InChI=1S/C18H26ClN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21)/i1D3,4D2
|
| Chemical Name |
4-N-(7-chloroquinolin-4-yl)-1-N-ethyl-1-N-(1,1,2,2,2-pentadeuterioethyl)pentane-1,4-diamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
